SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2026 / Volume: 2 Issue: 3

A case report of cutaneous and systemic lupus erythematosus after bupropion usage

Suat Akgür(Division of Nephrology, Kütahya University of Health Sciences Evliya Çelebi Eduaton and Research Hospital, Kütahya,Turkey)0000-0003-1745-6744
Saide Güllülü(Department of Internal Medicine, Yenişehir State Hospital, Bursa)0000-0001-6048-1879
Kamil Dilek(Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa)0000-0001-6149-1913
Oktay Ünsal(Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa)0000-0002-3215-8457
Mehmet Aydın(Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa)0000-0002-5665-7402
Ayşegül Oruç(Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa)0000-0002-0342-9692
Abdulmecit Yildiz(Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa)0000-0001-5941-9103
Mahmut Yavuz(Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa)0000-0001-6755-6386
Mustafa Güllülü(Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa)0000-0002-8911-7189
Alparslan Ersoy(Division of Nephrology, Department of Internal Medicine, Uludag University Faculty of Medicine, Bursa)0000-0002-0710-0923
Pages
—
Publication Date
2020-07-29
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient was diagnosed with cutaneous and systemic lupus erythematosus.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bupropion is a drug used to smoke cessation.
📊
Key Findings & Data:In a 58-year-old female patient, skin findings and anti-Ro52 positivity developed after the use of this drug.
💡
Conclusion & Impact:The patient was diagnosed with cutaneous and systemic lupus erythematosus.
🔬Design:Case Report
📍Scope:Comprehensive Sample
⚙️Variables:Bupropion · drug reaction · lupus-like syndrome

Abstract

Bupropion is a drug used to smoke cessation. Various complications have been reported after using this drug. In a 58-year-old female patient, skin findings and anti-Ro52 positivity developed after the use of this drug. Later, signs of vasculitis appeared under immunosuppressive therapy. The patient was diagnosed with cutaneous and systemic lupus erythematosus.

🔖

Cite This Article

Akgür, S., Güllülü, S., Dilek, K., Ünsal, O., Aydın, M., Oruç, A., Yildiz, A., Yavuz, M., Güllülü, M., Ersoy, A. (2020). A case report of cutaneous and systemic lupus erythematosus after bupropion usage. Turkish Journal of Internal Medicine, Volume: 2 Issue: 3. https://doi.org/10.46310/tjim.679421

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (26)

  1. Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev. 2005;4(5):253-63.
  2. Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007;33(1-2):85-106.
  3. Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol. 2011;165(2):335-41. doi: 10.1111/j.1365-2133.2011.10397.x.
  4. Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol. 2012;166(1):29-35. doi: 10.1111/j.1365-2133.2011.10610.x.
  5. Grönhagen CM, Fored CM, Linder M, Granath F, Nyberg F. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol. 2012;167(2):296-305. doi: 10.1111/j.1365-2133.2012.10969.x.
  6. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R, Ha E, Anhalt GJ, Provost TT, Nousari CH. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol. 2003;139(1):45-9.
  7. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol. 2001;137(9):1196-8.
  8. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009;301(1):65-70. doi: 10.1007/s00403-008-0890-x.
  9. Fays S, Tréchot P, Schmutz JL, Cuny JF, Truchetet F, Barbaud A. Bupropion and generalized acute urticaria: eight cases. Br J Dermatol. 2003;148(1):177-8.
  10. Chiavérini C, Baldin B, Chichmanian R-M, Ortonne J-P, Lacour J-P. Bupropion (ZybanÓ) induced urticaria: 2 cases. Annales de Dermatologie et de Vénéréologie. 2003;130(2):208-9. Doi: AD-02-2003-130-2-0151-9638-101019-ART15.
  11. Benson E. Bupropion-induced hypersensitivity reactions. Med J Aust. 2001;174(12):650-1.
  12. Olsen NJ. Drug-induced autoimmunity. Best Pract Res Clin Rheumatol. 2004;18(5):677-88.
  13. Aguirre Zamorano MA1, López Pedrera R, Cuadrado Lozano MJ. Drug-induced lupus. Med Clin (Barc). 2010;135(3):124-9. doi: 10.1016/j.medcli.2009.04.035.
  14. Love LA. New environmental agents associated with lupus-like disorders. Lupus. 1994;3(6):467-71.
  15. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet. 2002;359(9306):579-80.
  16. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum. 2003;48(4):1015-23.
  17. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166-82.
  18. Yung RL, Johnson KJ, Richardson BC. New concepts in the pathogenesis of drug-induced lupus. Lab Invest. 1995;73(6):746-59.
  19. Sen D, Isenberg DA. Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus. 2003;12(9):651-8.
  20. Vasoo S. Drug-induced lupus: an update. Lupus. 2006;15(11):757-61.
  21. Jumez N, Dereure O, Bessis D, Guillot B. Flare of cutaneous lupus erythematosus induced by bupropion (Zyban). Dermatology. 2004;208(4):362.
  22. Cassis TB, Callen JP. Bupropion-induced subacute cutaneous lupus erythematosus. Australas J Dermatol. 2005 Nov;46(4):266-9.
  23. Hannah CE, Little AJ, Wanat KA, Fairley JA. Drug-Induced Cutaneous Lupus Erythematosus: A Case Series of Five Patients with Bupropion-Associated Disease. J Clin Rheumatol. 2018. doi: 10.1097/RHU.0000000000000882.
  24. Barile-Fabris L, Hernández-Cabrera MF, Barragan-Garfias JA. Vasculitis in systemic lupus erythematosus. Curr Rheumatol Rep. 2014;16(9):440. doi: 10.1007/s11926-014-0440-9.
  25. Ramos-Casals M, Nardi N, Lagrutta M, Brito-Zerón P, Bové A, Delgado G, Cervera R, Ingelmo M, Font J. Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. Medicine (Baltimore). 2006;85(2):95-104.
  26. Chiavérini C, Baldin B, Chichmanian R-M, Ortonne J-P, Lacour J-P. Bupropion (ZybanÓ) induced urticaria: 2 cases. Annales de Dermatologie et de Vénéréologie. 2003;130(2):208-9. Doi: AD-02-2003-130-2-0151-9638-101019-ART15.